Big Pharma wants more CRO buy-in; Icon names new EVP;

> Big Pharma sponsors say CRO partnerships would be more effective if contractors were more engaged in the development process. Article

> Icon ($ICLR) has appointed Neil McCullough, a veteran of PPD and Pfizer ($PFE), to be its executive vice president of quality and compliance and corporate training. News

> Canadian CRO Ethica Clinical Research is reaching out to Alion Science and Technology to further accredit its human research programs. Story

> CRO Chiltern has named a new medical director and director of strategic partnerships, moves the company said will help it drive growth around the globe. More

> Antonella Mancuso, Patheon's president of global commercial operations and chief manufacturing officer, plans to resign from the company July 10. Report

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.